Size and Curvature Claims Have No Safe Register

what did FDA say about 'increase in length and thickness' and 'correct mild penis curvature'?

FDA treated both phrases as proof of a drug's intended use, not as marketing color. In its January 8, 2024 letter to Dr. Joel Kaplan Inc. (CMS 667193, following a June 2023 inspection), the agency cited insert language promising the MegaVac Pump System and DEEP: The Ultimate Penis Extender would deliver an 'increase in length and thickness' or 'correct mild penis curvature,' concluding the wording would "show an intent for use in the treatment of disease or other conditions." That sentence pulled the pumps into FD&C Act 201(h), FDA's category for non-ingested tools, rather than leaving them as cosmetic accessories.

That's a device-law finding under section 201(h), not a supplement-law finding under DSHEA, 1994's supplement statute.

Sell the same pitch on a capsule instead of a pump, and the analysis shifts to 21 CFR 101.93(g), FDA's ten-part test for a claim the product treats disease. Curvature correction maps onto trigger (ii), effect on the "characteristic signs or symptoms" of a named condition. Size alone has no comparable FDA ruling either way: no letter has called a bare inches-and-girth claim a disease claim, and none has cleared it. Don't treat the silence as permission for your landing page.

why does a curvature claim carry a lower ceiling than a generic enhancement claim?

Curvature reads as a symptom, and size reads as a metric — that's the real difference. A curvature claim borrows the vocabulary doctors use for Peyronie's disease, a condition involving scar tissue and painful bending, even when the copy never names it, and FDA's disease-claim test treats symptom language in "scientific or lay terminology" the same way it treats a clinical name. Size claims don't attach to any comparably specific condition, so they fail on different ground: insufficient evidence under the FTC's clinical-trial standard, not an automatic disease-claim trip wire.

Peyronie's disease is our inference from the symptom pattern, not a finding FDA has published.

Buyers in this niche often assume a size number is the safer claim because it avoids disease vocabulary entirely — we'd argue that's backwards. A number invites the FTC's substantiation floor, randomized controlled trials measuring an outcome nobody in this category has published, while curvature at least sits inside a narrower box FDA has already drawn. The same allowed-symptom, forbidden-symptom split shows up across verticals; the pattern in spider veins versus varicose veins is a clean parallel worth reading against this one.

did attributing the outcome to users rather than the seller shield the claim?

No — attribution to users didn't move the needle. The same Kaplan letter quotes the product insert verbatim: "Users report an increase in length and thickness . . . or correction of mild penis curvature." FDA cited that sentence as evidence of the firm's own intended use, treating "users report" as marketing copy rather than as a wall separating the seller from the claim.

Testimonial phrasing doesn't create legal distance.

The lesson generalizes past pumps. Any "users say" or "customers report" framing on a capsule page carries the same exposure the moment the underlying claim would be a disease claim if the seller said it directly — attribution changes the sentence's grammar, not its regulatory classification.

how did FDA treat 'energy' and 'stamina' product names as evidence of drug intent?

FDA treated 'energy' and 'stamina' branding as camouflage it could see straight through, not as a safe harbor. In its December 20, 2023 letter to Amazon.com, Inc. (CMS 662503), FDA bought seven products through Fulfillment by Amazon, where Amazon stores and ships it, and confirmed undeclared tadalafil in 'Round 2,' 'Genergy' and 'X Max Triple Shot Energy Honey,' plus undeclared sildenafil in 'WeFun' and 'Mens Maximum Energy Supplement.' The 'Round 2' label promised strength, energy and endurance; FDA read that as evidence of an unapproved drug, not a supplement claim.

Euphemism didn't lower the stakes; it raised them, because FDA cited the label copy itself as its evidence.

If your landing page or Amazon listing leans on 'energy,' 'stamina' or 'performance' language while an undeclared prescription ingredient sits in the formula, you're not avoiding the claim — you're the evidence FDA already knows how to read.

when does the brand name become the violation before any copy is written?

The brand name becomes the violation the moment it names or evokes a specific disease, before a single line of sales copy runs. Under 21 CFR 101.93(g)(2)(iv)(A), the name of the product is an independent trigger for disease-claim status on a dietary supplement label, separate from body copy, images or ingredient citations. A name built around size or hardness doesn't automatically cross that line; a name that evokes impotence, erectile dysfunction or a diseased prostate does.

We checked FDA's Sexual Enhancement and Energy Product Notifications list on August 7, 2026 and counted 431 entries total, 21 of them added in 2026 alone, almost all flagged for hidden sildenafil or tadalafil.

None of the names below mention disease. All of them shipped an undeclared prescription drug — the finding was chemical, not linguistic.

what does the marketplace liability in the Amazon letter mean for sellers on that channel?

It means the platform, not just the individual listing, can be treated as the point of introduction into interstate commerce, and a warning letter can name the marketplace instead of, or alongside, the seller. FDA's December 2023 letter held Amazon.com, Inc. itself responsible for introducing unapproved new drugs into commerce because it fulfilled and shipped the products through FBA, not merely hosted a listing.

That finding matters more to a third-party seller than it first looks like it should, because platform-level liability doesn't erase seller-level liability underneath it; it stacks on top. A seller whose product FDA finds contaminated with undeclared sildenafil or tadalafil still faces the standard unapproved-new-drug chain under sections 301(d) and 505(a), still faces misbranding exposure under 502(f)(1) if the labeling can't carry adequate directions for self-use, and now also sits inside a marketplace the agency has already flagged publicly by name. Sourcing matters too: a formula manufactured or contract-packed overseas adds an import layer FDA and Customs both watch, and the supply question behind any of these offers, which markets actually have manufacturers willing to fill them, is covered in which countries actually have offer inventory, a separate read worth doing before you pick a fulfillment channel.

how does Google treat this category as restricted merchandise and prohibited substance at once?

Google runs two separate policies over the same product at the same time, and either one alone can kill the ad. Its Sexual content policy classifies 'sexual enhancers' as 'sexual merchandise,' restricted rather than banned, gated by the viewer's age, the local laws where the ad serves, and SafeSearch, Google's explicit-content filter. Its Healthcare and medicines policy runs alongside it and separately bars "Products that imply they're as effective as prescription drugs or controlled substances" regardless of any claims of legality, which is exactly what a 'works like Viagra' pitch runs into.

Restricted and prohibited stacking means a compliant sexual-merchandise ad can still be pulled the moment the copy implies drug-equivalent effectiveness.

Meta is a harder read. Transparency.meta.com renders its Advertising Standards client-side, and every path we tried for this niche's health-and-wellness rule returned no usable text; we could not verify Meta's specific prohibitions on curvature or size claims from source, and the only way to settle it is reading the live policy page directly before a campaign relies on it. What actually gets through Meta's review in practice, separate from the published rule, is the subject of Male Enhancement Ads on Facebook: What Gets Through.

which recurring creative devices in this niche have already been cited by name?

Three creative devices recur across the enforcement record, and each has already been quoted in a federal letter. The hydraulic-growth story fuses expansion and a size outcome in one sentence; FDA quoted the Kaplan insert's own claim that a pumping routine "expands and grows the blood vessels that bring blood flow into the penis, leading to bigger, harder erections."

The user-attribution device, crediting the outcome to 'users report' rather than the seller, is the second, and the section above shows it failing on its own terms. The third is euphemism substitution: swapping 'energy,' 'stamina' or 'performance' for the prohibited term, which the Amazon letter pierced by citing the label copy itself as evidence, not the ingredient list.

A fourth device belongs to a neighboring niche but shows up in male enhancement funnels anyway: the DHT or hormone 'root cause' explainer that borrows prostate vocabulary to sound clinical. That mechanism story carries its own seasonal and disease-adjacent baggage, covered in Prostate Offer Seasonality: Movember and the Male Window, and importing it into a male enhancement page just adds a second disease's exposure to the first.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Gut Health VSL Intelligence, How Money Is Actually Made in Nutra — Four Roles, Four Economics, Peptide Offers: What's Running, and the Rules That Govern Them, Testosterone Booster Offers: Scaling Ads & Angles 2026, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.